What is already known about this subject
• The effectiveness and safety of rivaroxaban in stroke prevention of AF patients varied among studies (RCTs and observational studies).
• Difference in patient characteristics could be a common barrier leading to the outcome discrepancies across studies. Besides, difference in data source, outcome measures, and patient adherence, as well as confounding bias of observational studies, all contribute to the discrepant results.